Funding update
Mercia Ventures has continued its support into Invizius by leading a £950,000 funding round.
What is acute kidney injury? A visual guide
Early detection and prompt treatment could prevent long-term health effects of acute kidney injury, a condition that commonly arises while people are in hospital.
Invizius presents findings from First-In-Human Phase 1 Clinical Study of H-Guard® at UK Kidney Week
Invizius was pleased to attend UK Kidney Week, the UK’s largest conference for the professional kidney community, which was held in Edinburgh from 11-13 July.
We are delighted that Dr Duha Illyas’ Abstract on our COMPACT HD Study won ‘Best Abstract’ at the 61st ERA Congress in Stockholm last week.
We are delighted that Dr Duha Illyas’ Abstract on our COMPACT HD Study won ‘Best Abstract’ at the 61st ERA Congress in Stockholm last week. Her presentation revealed, for the first time, in depth kinetic and biomarker data on filter-initiated complement activation on chronic kidney disease (CKD) patients undergoing haemodialysis (HD).
Invizius’s Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study
22nd May 2024
- Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis.
- Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubule cell damage during Continuous Renal Replacement Therapy (CRRT).
Invizius Limited (“Invizius”), a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce that eight patients have been successfully treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with pioneering product, H-Guard® Priming Solution, in the company’s first-in-human Phase 1 clinical study.
Invizius Treats First Patients in First-In-Human Phase 1 Clinical Study of lead dialysis product H-Guard®
7th February 2024
Invizius, a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce that the first two patients have been treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) with lead product, H-Guard® Priming Solution, in the Company’s first-in-human Phase 1 clinical study.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved continuation of the study, following the submission of safety and performance data from the first two patients.
Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board
24th October 2023
Invizius, a biotechnology company developing breakthrough treatments for patients on dialysis, is pleased to announce the appointment of Professor Bernard Canaud to its Clinical Advisory Board. Professor Canaud is a leading authority on kidney disease and dialysis. He has over 40 years of experience in the field, has published more than 350 peer-reviewed articles on the subject, and in 2009 was awarded the Legion d’Honneur – the highest French order of merit. He served as Chief Medical Officer for Fresenius Medical Care from 2012 to 2018, and as its global Chief Medical Scientist from 2019 to 2021.
Invizius Receives MHRA Approval to Commence First-in-Human Clinical Study of H-Guard® Priming Solution
1st August 2023
Invizius, a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence its First-in-Human clinical study of lead product, H-Guard. The study will be conducted at the Manchester University Hospitals NHS Foundation Trust (MFT) and will be led by Professor Sandip Mitra and Co-investigators Dr Leonard Ebah and Dr Duha Ilyas.
Invizius announces ‘Angry Blood’ Haemodialysis Study and recruits its 300th patient
13th June 2023
Invizius, a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, is pleased to announce that it has recruited its 300th patient to the ‘Angry Blood’ study. This is a significant milestone in its novel kinetic study to identify patients with elevated complement responses during haemodialysis (HD), so-called ‘angry blood,’ who may have a high risk of serious cardiovascular complications, the major cause of mortality in HD patients.
Appointment of Professor Peter Stenvinkel to Clinical Advisory Board
13th July 2022
Invizius, a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, is pleased to announce the appointment of Professor Peter Stenvinkel (pictured right) to its Clinical Advisory Board. Professor Stenvinkel is a world-renowned expert senior lecturer at Karolinska University Hospital and Professor of Nephrology at Karolinska Institutet (KI), Stockholm, Sweden.
Second grant win to research Peritoneal Dialysis indication
26th April 2022
Invizius, a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant from Innovate UK to research a new field of application for its H-Guard® technology. The company will assess in-vitro and in-vivo efficacy of a novel method of using its technology for Peritoneal Dialysis and progress thereafter into pre-clinical development.
Major Biomedical Catalyst grant win
30th March 2022
Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of haemodialysis, to the clinic. The funds will be used towards H-Guard’s First-in-Man safety study commencing in 2022.
Invizius announces £5.3m Series A
6th May 2021
Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of £5.3 million. The financing was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. Although already over-subscribed, the company’s Series A remains open to other investors until June 2021.
Solvay invests in Invizius
Feb. 2020
Solvay Ventures announces today its equity investment in Invizius, the University of Edinburgh spin-out developing potentially lifesaving products that reduce complications rates suffered by dialysis patients. Solvay Ventures invests alongside Mercia Asset Management, Downing Ventures, the University of Edinburgh’s Old College Capital fund and the Scottish Investment Bank.
Invizius appoints industry heavyweights
Invizius attracts £2.75m investment
Oct. 2019
Invizius, the Univerity of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75m from a consortium of investors.
Invizius named "Fierce 15" company
Feb. 2019
Invizius has been named by FierceMedTech as one of 2018’s Fierce 15 med tech companies, designating it as one of the most promising private companies in the industry.
Invizius named ‘Best Innovative MedTech’
Oct. 2018
Invizius has been named Best Innovative MedTech company at the prestigious OBN Awards.
Invizius secures £0.5m investment
Apr. 2018
University of Edinburgh spinout, Invizius, has secured £0.5m seed investment from Mercia Fund Managers.
